342 results about "Cognition.knowledge" patented technology

A smart phone senses audio, imagery, and / or other stimulus from a user's environment, and acts autonomously to fulfill inferred or anticipated user desires. In one aspect, the detailed technology concerns phone-based cognition of a scene viewed by the phone's camera. The image processing tasks applied to the scene can be selected from among various alternatives by reference to resource costs, resource constraints, other stimulus information (e.g., audio), task substitutability, etc. The phone can apply more or less resources to an image processing task depending on how successfully the task is proceeding, or based on the user's apparent interest in the task. In some arrangements, data may be referred to the cloud for analysis, or for gleaning. Cognition, and identification of appropriate device response(s), can be aided by collateral information, such as context. A great number of other features and arrangements are also detailed.

A novel display control and information management system seamlessly integrates layered and slotted formatted data from local and remote sources to provide a highly versatile information display. The system permits selective control of display and display features so that complex data and data flows can be seamlessly accessed with enhanced cognition of salient information by a user.

This application relates to information analysis and more particularly to a system and method for interactive visual representation of information content and relationships using layouts and gestures. A visualization tool is provided which facilitates both ad-hoc and more formal analytical tasks as a flexible and expressive thinking environment. The tool provides a space focused on ‘Human Interaction with Information’ and enabling evidence marshalling. Capabilities of the tool include put-this-there cognition, automatic analysis templates, and gestures for the fluid expression of thought and scalability mechanisms to support large analysis tasks.

The present disclosure relates to methods and tools for enhancing cognition and improving well being in an individual. The methods involve presenting to an individual a task to be performed, presenting to the individual an interference, and receiving inputs from the individual. Where the interference is a distraction, the individual is to ignore the interference. Where the interference is an interruptor, the individual is instructed to respond to the interruptor as a secondary task and is said to be multi-tasking. Inputs are then also received from the individual pertaining to this secondary task. The methods encompass iterations of these presentating steps and receiving of the input, and generation of analysis and / or feedback to the individual. The methods can further include conducting an analysis and / or generating feedback to the individual. The analysis can include a comparison of the performances with or without each type of interference.

Described herein, in certain embodiments, are devices and methods for modulating the electrical activity of a brain in a targeted manner using a weak magnetic field, generally field with a strength of less than about 100 Gauss. The magnetic field is varied over time in a periodic manner, generally with a frequency tuned to specifically affect one of the intrinsic frequencies of the brain, optionally the alpha frequency. The “Low Field Magnetic Stimulation” devices and methods described herein modulate the electrical activity of a brain without requiring medication. Methods and devices described herein gently “tune” the brain and affect mood, focus, and cognition of human subjects.

The invention provides improved agents and methods for treatment of diseases associated with beta amyloid (Aβ). Preferred agents include antibodies, e.g., humanized antibodies specific for Aβ.

A smart phone senses audio, imagery, and / or other stimulus from a user's environment, and acts autonomously to fulfill inferred or anticipated user desires. In one aspect, the detailed technology concerns phone-based cognition of a scene viewed by the phone's camera. The image processing tasks applied to the scene can be selected from among various alternatives by reference to resource costs, resource constraints, other stimulus information (e.g., audio), task substitutability, etc. The phone can apply more or less resources to an image processing task depending on how successfully the task is proceeding, or based on the user's apparent interest in the task. In some arrangements, data may be referred to the cloud for analysis, or for gleaning. Cognition, and identification of appropriate device response(s), can be aided by collateral information, such as context. A great number of other features and arrangements are also detailed.

The invention discloses a back sight image cognition based on-vehicle blind area early warning system and a method, wherein the system is composed of cameras (1 and 2) mounted on a rearview mirror to monitor the blind area, a digital signal processor (DSP), a sound prompting device, a power source and a plurality of data cables. The system reads the automobile travelling signal through the data cables, acquires the road surface image of the blind area (4 and 5) by adopting the rearview cameras, the processor processes the image, detects the automobile (3) in the blind area, analyzes the travelling state of the automobile, and realizes the multi-stage tracking for the automobile, when the driver intends to switch lanes, if another automobile in the blind area is not far from the automobile, then the driver is warned by the sound prompting device, so that the danger of collision during switching lanes is avoided. The back sight image cognition based on-vehicle blind area early warning system and the method are applied to the active safety driving, and has the advantages of simple system configuration, low cost, high safety performance, good real-time performance and complex environment adaptability.

In general, the invention relates to a pharmaceutical dose having R-flurbiprofen as the active ingredient that upon oral administration of a single dose to a fasting subject provides a Cmax of about 30-95 μg per mL. When the dose is administered to an individual having mild-to-moderate Alzheimer's disease (or desiring protection against Alzheimer's disease) twice daily for at least 4 months according to the described guidelines, an improvement or lessening in decline of cognitive function as characterized by cognition tests is observed in the patient. The composition of the invention is formulated with one or more pharmaceutically acceptable excipients, salts or carriers.

Methods and devices for providing therapeutic electromagnetic field treatment to a subject having a cognitive or neurological condition or injury. Treatment devices can include headwear incorporating electromagnetic treatment delivery devices providing electromagnetic treatment to a user's head area. Such devices include protective headwear such as helmets with electromagnetic delivery devices. Additionally, embodiments of the invention provide for wearable and adjustable electromagnetic treatment devices that can be used to provide electromagnetic treatment to multiple areas of the user's head. Embodiments of the invention provide for sequential electromagnetic treatment with a single or a plurality of treatment applicators which target a single or multiple cerebral regions as determined by imaging, non-imaging and physiological monitoring before, during and after electromagnetic treatment.

Compositions, kits, methods, and systems to induce, maintain, monitor, and interpret a continuous, un-fragmented REM sleep state in humans, generate dreams, recover sleep, create brain neuronal plasticity and activate the brain for cognition enhancement and mood stabilization are described. If potentially combined with other medications, a platform is provided to develop new research and therapies in many fields treating the human brain. The procedure reliably and quickly generates a Continuous REM Sleep cycle of pre-determined time or indefinite duration depending on therapeutic goals, allowing the patient to experience a qualitatively superior dream sleep in a shortened period of time compared to a natural sleep cycle. Profuse positive (pleasant) dreams are produced as well. REM sleep, dreams and sleep recovery can be reliably generated, and various sleep, psychological and neurological illnesses and disorders can be treated or prevented either solely by this method or in combination with additional agents.

The present invention relates to pharmaceutical compositions and formulations comprising a novel class of androgen receptor targeting agents (ARTA) which demonstrate androgenic and anabolic activity of a nonsteroidal ligand for the androgen receptor. The agents define a new subclass of compounds which are selective androgen receptor modulators (SARM) which are useful for a) male contraception; b) treatment of a variety of hormone-related conditions, for example conditions associated with Androgen Decline in Aging Male (ADAM), such as fatigue, depression, decreased libido, sexual dysfunction, erectile dysfunction, hypogonadism, osteoporosis, hair loss, anemia, obesity, sarcopenia, osteopenia, osteoporosis, benign prostate hyperplasia, alterations in mood and cognition and prostate cancer; c) treatment of conditions associated with Androgen Decline in Female (ADIF), such as sexual dysfunction, decreased sexual libido, hypogonadism, sarcopenia, osteopenia, osteoporosis, alterations in cognition and mood, depression, anemia, hair loss, obesity, endometriosis, breast cancer, uterine cancer and ovarian cancer; d) treatment and / or prevention of chronic muscular wasting; and / or e) decreasing the incidence of, halting or causing a regression of prostate cancer. The present invention provides pharmaceutical compositions comprising the selective androgen receptor modulator compounds, together with pharmaceutically acceptable excipients.

This invention provides androgen receptor targeting agents (ARTA). The agents define a new subclass of compounds, which are selective androgen receptor modulators (SARM). Several of the SARM compounds have been found to have an unexpected androgenic and anabolic activity of a nonsteroidal ligand for the androgen receptor. Other SARM compounds have been found to have an unexpected antiandrogenic activity of a nonsteroidal ligand for the androgen receptor. The SARM compounds, either alone or as a composition, are useful for a) male contraception; b) treatment of a variety of hormone-related conditions, for example conditions associated with Androgen Decline in Aging Male (ADAM), such as fatigue, depression, decreased libido, sexual dysfunction, erectile dysfunction, hypogonadism, osteoporosis, hair loss, anemia, obesity, sarcopenia, osteopenia, osteoporosis, benign prostate hyperplasia, alterations in mood and cognition and prostate cancer; c) treatment of conditions associated with Androgen Decline in Female (ADIF), such as sexual dysfunction, decreased sexual libido, hypogonadism, sarcopenia, osteopenia, osteoporosis, alterations in cognition and mood, depression, anemia, hair loss, obesity, endometriosis, breast cancer, uterine cancer and ovarian cancer; d) treatment and / or prevention of acute and / or chronic muscular wasting conditions; e) preventing and / or treating dry eye conditions; f) oral androgen replacement therapy; and / or g) decreasing the incidence of, halting or causing a regression of prostate cancer

Disclosed are RAGE antagonist compounds that have the ability to reverse pre-existing amyloidosis. Treatment with the RAGE antagonist compounds described herein may be used to reduce plaque size and improve cognition for subjects in the later stages of Alzheimer's disease. Additionally, the RAGE antagonists described herein may be used to reduce the onset of plaque formation and thereby prevent loss of cognition and other symptoms associated with Alzheimer's Disease and other diseases of amyloid deposition.

The present invention relates to a synthetic process for the preparation of a novel class of androgen receptor targeting agents (ARTA) which demonstrate androgenic and anabolic activity of a nonsteroidal ligand for the androgen receptor. The agents define a new subclass of compounds which are selective androgen receptor modulators (SARM) which are useful for a) male contraception; b) treatment of a variety of hormone-related conditions, for example conditions associated with Androgen Decline in Aging Male (ADAM), such as fatigue, depression, decreased libido, sexual dysfunction, erectile dysfunction, hypogonadism, osteoporosis, hair loss, anemia, obesity, sarcopenia, osteopenia,osteoporosis, benign prostate hyperplasia, alterations in mood and cognition and prostate cancer; c) treatment of conditions associated with Androgen Decline in Female (ADIF), such as sexual dysfunction, decreased sexual libido, hypogonadism, sarcopenia, osteopenia, osteoporosis, alterations in cognition and mood, depression, anemia, hair loss, obesity, endometriosis, breast cancer, uterine cancer and ovarian cancer; d) treatment and / or prevention of chronic muscular wasting; e) decreasing the incidence of, halting or causing a regression of prostate cancer; f) oral androgen relacement and / or other clinical therpauetic and / or diagnostic areas. The process of the present invention is suitable for large-scale preparation, since all of the steps give rise to highly pure compounds, thus avoiding complicated purification procedures which ultimately lower the yield. Thus the present invention provides methods for the synthesis of non-steroidal agonist compounds, that can be used for industrial large-scale synthesis, and that provide highly pure products in high yield.

The present invention relates to the enhancement of cognition in an individual by delivery of a histone acetylation regulator, such as a histone deacetylase inhibitor. The individual may have normal or poor memory, and the poor memory may be the result of a pathogenic condition or a non-pathogenic condition, such as with normal aging-related impairment. In a specific embodiment, enhancement of cognition occurs in an individual having a mental retardation syndrome.

The invention provides a test system of a stimulus information cognition ability value, comprising a stimulus information providing device, a sight tracking device, a feedback data acquisition device, a cognition index value analysis device, a cognition accuracy degree analysis device and a cognition ability value computing device. The stimulus information providing device shows vision and audition stimulus information for a tester; the sight tracking device tracks and records the motion state of eyes of a tester in the process of acquiring and processing the vision stimulus information; the feedback data acquisition device is used for acquiring feedback data input by the tester responding to the stimulus information; the cognition index value analysis device acquires a cognition index value of the tester in the process of processing the vision stimulus information according to the record of the sight tracking device through a visual motion analysis method; the cognition accuracy degree analysis device computes the cognition accuracy degree of the tester according to the content of the feedback data; and the cognition ability value computing device computes obtained standard scores for representing the comprehensive cognition ability of the tester according to the cognition index value and the cognition accuracy degree through a statistic method. The test system can more accurately record the cognition process of the tester and the difference of the cognition ability among testers and can also be widely applied in the fields of talent selection, job placement, learning ability diagnosis, advertising effect, safety training of drivers, and the like.

The invention provides a method and device for recognizing malicious users, and belongs to the field of network technology. The method includes the steps that historical behavior characteristics of a user to be recognized are acquired; a user classification model is acquired, wherein the user classification model is generated through classifier model training based on historical behavior characteristics of malicious users and historical behavior characteristics of normal users; the historical behavior characteristics of the user to be recognized are input into the user classification model to determine whether the user to be recognized is a malicious user or not. Through the user classification model obtained through classifier model training, the behavior characteristics of malicious users can be automatically analyzed according to the characteristics of a machine learning algorithm; compared with the prior art, the method and device have the advantages that the recognition process is independent of the subjective cognition of the human, and the coverage scope of behavior characteristics is wider, so that misjudgment and missed judgment are effectively reduced, and the accuracy of recognizing malicious users is improved.

A method on a computing device is provided for enhancing the memory and cognitive ability of an older adult by requiring the adult to differentiate between rapidly presented stimuli. The method trains the time order judgment of the adult by presenting upward and downward frequency sweeps, in random order, separated by an inter-stimulus interval. The upward and downward frequency sweeps are at frequencies common in formants which form the frequency components common in speech. Icons are associated with the upward and downward frequency sweeps to allow the adult to indicate an order in which the frequency sweeps are presented (i.e., UP-UP, UP-DOWN, DOWN-UP, and DOWN-DOWN). Correct selection of an order causes the inter-stimulus interval to be reduced, and / or the duration of the frequency sweeps to be adaptively shortened.

Computer-implemented method for enhancing a participant's cognition, including, e.g., visual memory, utilizing a computing device to present visual stimuli for training, and to record responses from the participant. Multiple graphical elements are provided for visual presentation to the participant. A temporal sequence of a plurality of the graphical elements is visually presented, including displaying each graphical element in the sequence at a respective location in a visual field for a specified duration, then ceasing to display the graphical element. The presented graphical elements include at least two matching graphical elements. The participant is required to respond to the presented sequence, including indicating locations of matching graphical elements. A determination is made as to whether the participant responded correctly, and the duration modified based on the determining. The visually presenting, requiring, determining, and modifying are repeated one or more times in an iterative manner to improve the participant's cognition.

In one embodiment, this invention provides a class of androgen receptor targeting agents (ARTA). The agents define a new subclass of compounds, which are selective androgen receptor modulators (SARM). The SARM compounds have unexpected antiandrogenic activity of a nonsteroidal ligand for the androgen receptor. In one embodiment, the SARM compounds bind irreversibly to the androgen receptor In another embodiment, the SARM compounds are androgen receptor antagonists, which bind irreversibly to the androgen receptor. In another embodiment, the SARM compounds are alkylating agents. The SARM compounds, either alone or as a composition, are useful for a) male contraception; b) treatment of a variety of hormone-related conditions, for example conditions associated with Androgen Decline in Aging Male (ADAM), such as fatigue, depression, decreased libido, sexual dysfunction, erectile dysfunction, hypogonadism, osteoporosis, hair loss, anemia, obesity, sarcopenia, osteopenia, osteoporosis, benign prostate hyperplasia, alterations in mood and cognition and prostate cancer; c) treatment of conditions associated with Androgen Decline in Female (ADIF), such as sexual dysfunction, decreased sexual libido, hypogonadism, sarcopenia, osteopenia, osteoporosis, alterations in cognition and mood, depression, anemia, hair loss, obesity, endometriosis, breast cancer, uterine cancer and ovarian cancer; d) treatment and / or prevention of acute and / or chronic muscular wasting conditions; e) preventing and / or treating dry eye conditions; f) oral androgen replacement therapy; g) decreasing the incidence of, halting or causing a regression of prostate cancer; and / or h) inducing apoptosis in a cancer cell.

Computer-implemented method for improving cognition. Multiple first and second stimulus elements are provided, where some of the second elements correspond to the first elements. A sequence of first stimulus elements is presented, each element presented for a duration separated by an interval. After a specified delay period, equal to the duration plus the interval, times a non-integer factor N, a sequence of groups of second elements is presented concurrently with the sequence of first elements, where each group includes a matching second element that matches a corresponding first element presented earlier by the specified delay period, i.e., presented N first elements back. For each presented group, the participant indicates the matching second element, or a second element in the group that doesn't match. The delay period is modified based on whether the participant responded correctly. The presenting, presenting, requiring, determining, and modifying are repeated in an iterative manner.

An audible distance measurer object-face discriminator cognition stimulant system device housed in a handheld shaft, walking stick, belt attachment, or portable housing. The system device will capture, detect, merge, convert, process, compute and / or synthesize signals, measurements, images, objects-faces, colors, and shapes to output assistive phrases and measurements in electronic voice, to inform and make the user knowledgeable of objects and aware of surroundings and environment directly in path of movement-direction pointed, comprising in combination strategically positioned signal receivers, transmitters or satellite, embedded distance measurer sensor, digital video camera, cellular phone, radio, electronic travel aid (ETA), electronic orientation aid (EOA), position locator device (PLD), embedded restroom facility locator sensor, and embedded vehicle presence alert system (VPAS) sensor, which will generally aid sighted and visually impaired students, teachers and students of the No Child Left Behind (NCLB) Act, and more particularly, the elderly, and visually impaired military war veterans in a Right to Personal Privacy, while simultaneously providing sighted and blind-visually impaired children with an educational toy and interactive game.

The present invention is a method for effecting rapid improvement in cognition in subjects suffering from conditions or diseases related to the Aβ peptide, including Alzheimer's disease, Down's syndrome, cerebral amyloid angiopathy, mild cognitive impairment, and the like. The method comprises administering anti-Aβ antibodies to the subject, especially antibodies having a high affinity for soluble forms of Aβ. X-15240

The present invention relates to androgen receptor targeting agents (ARTA) which demonstrate androgenic and anabolic activity, which are nonsteroidal ligands for the androgen receptor. The selective androgen receptor modulators (SARM) are useful for a) male contraception; b) treatment of a variety of hormone-related conditions, for example conditions associated with Androgen Decline in Aging Male (ADAM), such as fatigue, depression, decreased libido, sexual dysfunction, erectile dysfunction, hypogonadism, osteoporosis, hair loss, anemia, obesity, sarcopenia, osteopenia,osteoporosis, benign prostate hyperplasia, alterations in mood and cognition and prostate cancer; c) treatment of conditions associated with Androgen Decline in Female (ADIF), such as sexual dysfunction, decreased sexual libido, hypogonadism, sarcopenia, osteopenia, osteoporosis, alterations in cognition and mood, depression, anemia, hair loss, obesity, endometriosis, breast cancer, uterine cancer and ovarian cancer; d) treatment and / or prevention of chronic muscular wasting; e) decreasing the incidence of, halting or causing a regression of prostate cancer; f) oral androgen relacement and / or other clinical therpauetic and / or diagnostic areas.

This invention provides a composition comprising a 5-alpha reductase inhibitor and a class of androgen receptor targeting agents (ARTA), which are selective androgen receptor modulators (SARM). The compositions of this invention are useful for, inter-alia, a) male contraception; b) treatment of a variety of hormone-related conditions, for example conditions associated with Androgen Decline in Aging Male (ADAM), such as fatigue, depression, decreased libido, sexual dysfunction, erectile dysfunction, hypogonadism, osteoporosis, hair loss, anemia, obesity, sarcopenia, osteopenia, osteoporosis, benign prostate hyperplasia, alterations in mood and cognition and prostate cancer; c) treatment of conditions associated with Androgen Decline in Female (ADIF), such as sexual dysfunction, decreased sexual libido, hypogonadism, sarcopenia, osteopenia, osteoporosis, alterations in cognition and mood, depression, anemia, hair loss, obesity, endometriosis, breast cancer, uterine cancer and ovarian cancer; d) treatment of polycystic ovarian disease; e) treatment and / or prevention of acute and / or chronic muscular wasting conditions; f) preventing and / or treating dry eye conditions; g) oral androgen replacement therapy; h) decreasing the incidence of, halting or causing a regression of prostate cancer; and / or i) inducing apoptosis in a cancer cell.

The present invention relates to androgen receptor targeting agents (ARTA) which demonstrate androgenic and anabolic activity, which are nonsteroidal ligands for the androgen receptor. The selective androgen receptor modulators (SARM) are useful for a) male contraception; b) treatment of a variety of hormone-related conditions, for example conditions associated with Androgen Decline in Aging Male (ADAM), such as fatigue, depression, decreased libido, sexual dysfunction, erectile dysfunction, hypogonadism, osteoporosis, hair loss, anemia, obesity, sarcopenia, osteopenia, osteoporosis, benign prostate hyperplasia, alterations in mood and cognition and prostate cancer; c) treatment of conditions associated with Androgen Decline in Female (ADIF), such as sexual dysfunction, decreased sexual libido, hypogonadism, sarcopenia, osteopenia, osteoporosis, alterations in cognition and mood, depression, anemia, hair loss, obesity, endometriosis, breast cancer, uterine cancer and ovarian cancer; d) treatment and / or prevention of chronic muscular wasting; e) decreasing the incidence of, halting or causing a regression of prostate cancer; f) oral androgen relacement and / or other clinical therpauetic and / or diagnostic areas.

A control information conveyance structure comprises: a cognition-system control platform which recognizes the circumstances of the surroundings of a vehicle and generates a control space; an operation-system control platform which recognizes the circumstances related to the movement of the vehicle body and generates a control space; and a determination-system control platform which generates a determination control space based on information from the cognition-system and operation-system control platforms. The conveyance structure is constituted so that sensors and individual control devices belong to either or both of the control platforms. This control information conveyance structure is adopted. Thus, control platforms of such a control structure that the individual control devices are managed at a higher level can be provided.